Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Direct thrombin inhibitors.

Karen L Kaplan1, Charles W Francis

  • 1Hematology-Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.

Seminars in Hematology
|July 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Research and practice in thrombosis and haemostasis·2022
Same author

Vascular Imaging in the Asymptomatic High-risk Cancer Population: A Role for Thrombosis Screening and Therapy Management.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2021
Same author

American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Blood advances·2019
Same author

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2019
Same author

PGM Guidelines for Description of Criteria and Methods for Testing of Specificity of Assay Methods for Quantities in the Fibrinolytic System.

EJIFCC·2019
Same author

Approach to pancytopenia: Diagnostic algorithm for clinical hematologists.

Blood reviews·2018
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Direct thrombin inhibitors offer a targeted approach to anticoagulation by blocking thrombin activity. This review details approved and investigational direct thrombin inhibitors, including their chemical properties and clinical applications.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Hematology

Background:

  • Direct thrombin inhibitors (DTIs) represent a distinct class of anticoagulants.
  • Unlike heparin or warfarin, DTIs directly bind to thrombin, inhibiting its enzymatic function.
  • This mechanism offers a targeted approach to managing coagulation disorders.

Purpose of the Study:

  • To review the chemical structure, kinetics, pharmacokinetics, and clinical applications of currently approved and investigational direct thrombin inhibitors.
  • To differentiate the mechanism of action of DTIs from other anticoagulant classes.

Main Methods:

  • Literature review of direct thrombin inhibitors.
  • Analysis of chemical structures and inhibition kinetics.
  • Pharmacokinetic and clinical data evaluation.

Related Experiment Videos

Main Results:

  • Three DTIs (lepirudin, bivalirudin, argatroban) are approved for clinical use.
  • Melagatran/ximelagatran is in advanced clinical testing.
  • Detailed discussion on the properties and uses of each agent is provided.

Conclusions:

  • Direct thrombin inhibitors provide effective anticoagulation through direct thrombin blockade.
  • Understanding their distinct mechanisms and properties is crucial for optimal clinical use.
  • The development of new DTIs continues to expand therapeutic options in anticoagulation.